GLP-1 & Incretin Therapies

Featured Session · 01 of 35

Incretin-based pharmacotherapy has redefined obesity medicine, with semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) now delivering 15–22% mean weight loss in the STEP and SURMOUNT programs. GSOD 2027 will present long-term data including SELECT cardiovascular outcomes, SUMMIT in HFpEF-obesity, FLOW in diabetic kidney disease, and the MASH readouts that are reshaping hepatology. Sessions will also examine the next wave: retatrutide (GGG triple agonist), oral orforglipron, survodutide, CagriSema, mazdutide, and OASIS oral semaglutide — alongside supply, compounding exit, and Medicare coverage debates.

Topics covered in this session

SELECT, SURMOUNT-MMO and cardiovascular outcomes of GLP-1 RAs
Triple agonists: retatrutide GGG and survodutide phase 3 readouts
Oral incretins: orforglipron, OASIS oral semaglutide, danuglipron
CagriSema, mazdutide and amylin/glucagon co-agonism
SUMMIT HFpEF, FLOW kidney and ESSENCE MASH indication expansion
Weight regain on discontinuation and maintenance dosing strategies
Medicare coverage, compounded shortage exit and global access

Submit to this session All sessions

Other Sessions

Explore the full GSOD 2027 program

Open the full sessions overview